阿替普酶与培元通脑胶囊联用对急性脑梗死患者疗效及安全性的影响

Efficacy and Safety Influence of Alteplase Combined with Peiyuan Tongnao Capsule in the Treatment of Patients with Acute Cerebral Infarction

目的探讨阿替普酶与培元通脑胶囊联用对急性脑梗死患者疗效及安全性的影响。方法选取2019年5月到2020年5月在铁岭市中心医院新城院区接受治疗的ACI患者168例作为研究对象,按随机数字表法分为观察组与对照组,各84例。对照组给予阿替普酶治疗,观察组在此基础上采用培元通脑胶囊治疗。比较两组疗效,美国国立卫生研究院卒中量表(NIHSS)及改良Rankin量表(m RS)评分,以及安全性。结果观察组治疗有效率98.81%,明显高于对照组的90.48%(P<0.05)。治疗后,两组NIHSS及m RS评分较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率是7.14%,与对照组的5.95%比较,差异无统计学意义(P>0.05)。结论阿替普酶以及培元通脑胶囊联用对ACI患者的疗效及安全性较好,可有效改善患者的相关症状。

Objective To explore the efficacy and safety influence of alteplase combined with Peiyuan Tongnao Capsules in the treatment of patients with acute cerebral infarction(ACI).Methods A total of 168 ACI patients admitted to Tieling Central Hospital from May 2019 to May 2020 were selected as the research objects.According to the random number table,they were assigned into an observation group and a control group,with 84 cases in each group.The control group was treated with alteplase,and the observation group was treated with Peiyuan Tongnao Capsules plus alteplase.The efficacy,the National Institutes of Health Stroke Scale(NIHSS)and Modified Rankin Scale(m RS)scores,and safety were compared between the 2 groups.Results The total effective rate of the observation group was 98.81%,significantly higher than the control group of 90.48%(P<0.05).The NIHSS and mRS scores of the 2 groups after treatment were lower than before,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 7.14%,compared with the control group of 5.95%,the difference was not significant(P>0.05).Conclusion The efficacy and safety of the combination of alteplase and Peiyuan Tongnao Capsules are better in ACI patients.It can also improve the symptoms of patients.